TLR7/8 antagonists and uses thereof

A compound of formula I,

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is pyridyl;
• Ring B is pyridyl or pyrazinyl;
• R1 is —CHF2, —CH3, —F, —CF3, —OMe, or —CN;
• each R2 is independently —H, —C1-8 alkyl, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
• each R3 is independently —H, alkyl, -haloalkyl, and —CN;
• X is CH2 or O;
• each R4 is independently selected from the group consisting of
• each R5 is independently alkyl or -haloalkyl;
• each R is independently hydrogen, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each of which is optionally substituted, with the exception of H;
• or
• two R groups on the same atom are taken together with the atom to which they are attached to form a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each of which is optionally substituted;
• k is 0 or 1;
• n is 0, 1, or 2;
• p is 0, 1, or 2;
• r is 1 or 2;
• and
• t is 1 or 2.